Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007700 | 0.80 | TERT (0.32) | APPTERTTSHRKMT2AMEN1 | |
| SCHEMBL992959 | 0.72 | CYP1A2 (0.53) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL7108360 | 0.72 | S1PR2 (0.41) | ALDH1A1KMT2AMEN1S1PR2KDM4E | |
| SCHEMBL1760716 | 0.71 | TSHR (0.57) | APPTERTTSHRALDH1A1HSD17B10 | |
| SCHEMBL31168035 | 0.71 | CHRM2 (0.33) | APP | |
| SCHEMBL2193714 | 0.71 | GRM5 (0.51) | EGFR | |
| SCHEMBL7378456 | 0.71 | MAPT (0.49) | APPTERTTSHRALDH1A1HSD17B10 | |
| SCHEMBL3788304 | 0.71 | ALDH1A1 (0.42) | APPTERTTSHRALDH1A1HSD17B10 | |
| SCHEMBL1042705 | 0.71 | TSHR (0.50) | APPTERTTSHRALDH1A1HSD17B10 | |
| SCHEMBL2767944 | 0.71 | MAPT (0.33) | S1PR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024217523-A1 | SELECTIVE TKY2 INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2024-10-24 | — | — | WO | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| CN-111212833-B | Phenylpyridine derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2022-09-06 | — | — | CN | disclosed |
| EP-3696176-B1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | DAE WOONG PHARMA (KR) | 2022-05-04 | — | — | EP | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| WO-2014031784-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | ALIOS BIOPHARMA, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-0693490-B1 | 2-Phenoxy-6-thienylmethyloxypyridine derivative, process for producing the same, and herbicidal composition | KUREHA CHEMICAL IND CO LTD (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5624942-A | 2-phenoxy-6-thienylmethyloxypyridine derivative and herbicidal composition containing same | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-04-29 | — | — | US | disclosed |
| EP-0693490-A1 | 2-Phenoxy-6-thienylmethyloxypyridine derivative, process for producing the same, and herbicidal composition | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | APP 4880/4885TERT 2433/4885TSHR 4302/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | APP 4864/4885TERT 2659/4885TSHR 4424/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | APP 4864/4885TERT 2659/4885TSHR 4424/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | APP 4864/4885TERT 2659/4885TSHR 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.